Ro 25-6981

Cat. No.: HY-13993

CAS No.: 169274-78-6

Molecular Formula: $C_{22}H_{29}NO_2$

Molecular Weight: 339.47

Target: iGluR

Pathway: Membrane Transporter/Ion Channel; Neuronal Signaling

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.



SOLVENT & SOLUBILITY

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (7.36 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (7.36 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (7.36 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Ro 25-6981 is a potent, selective and activity-dependent NR2B subunit specific NMDA receptor antagonist. Ro 25-6981 shows anticonvulsant and anti-parkinsonian activity. Ro 25-6981 has the potential for the research of parkinson's disease (PD)[1][2][3].

IC_{50} & Target

NMDA Receptor

In Vivo

Ro 25-6981 (0.39-12.5 mg/kg; i.p.) induces contraversive rotations in 6-hydroxydopamine (6-OHDA)-lesioned rats without stimulating locomotion in normal rats[1].

Ro 25-6981 (1,3 mg/kg; i.p.) exhibits age- and activation-dependent anticonvulsant action at early postnatal development in rats[2].

Ro 25-6981 (800 μg; intrathecal injection) shows significant analgesic effects on incision pain in rats and effectively attenuated postoperative hyperalgesia[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6-OHDA-lesioned rats[1]
Dosage:	0.39-12.5 mg/kg
Administration:	I.p.
Result:	Dose-dependently induced contraversive tight nose-to-tail rotations, and induced a weak

	ipsiversive circling response indicating a mild unspecific stimulatory action of the compound.

Animal Model:	Male albino rats of Wistar strain[2]
Dosage:	1, 3 mg/kg
Administration:	I.p.
Result:	Caused a significant decrease of N1–P2 amplitude at higher stimulation intensities AT 3 mg/kg, and exhibited age- and activation-dependent anticonvulsant action at early postnatal development.

CUSTOMER VALIDATION

- Cell Death Differ. 2023 May 4.
- CNS Neurosci Ther. 2023 Jan 24.
- Neuropharmacology. 2022 Jan 10;108947.
- Sci Rep. 2022 Oct 12;12(1):17114.
- Neurochem Int. 2020 Dec 16;104942.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Löschmann PA, et al. Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease. Exp Neurol. 2004 May;187(1):86-93.

[2]. Szczurowska E,et al. Different action of a specific NR2B/NMDA antagonist Ro 25-6981 on cortical evoked potentials and epileptic afterdischarges in immature rats. Brain Res Bull. 2015 Feb;111:1-8.

[3]. Jiang M, et al. Antinociception and prevention of hyperalgesia by intrathecal administration of Ro 25-6981, a highly selective antagonist of the 2B subunit of N-methyl-D-aspartate receptor. Pharmacol Biochem Behav. 2013 Nov;112:56-63.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA